Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06265181
Other study ID # AIBU-SBF-SK-04
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 27, 2024
Est. completion date December 31, 2027

Study information

Verified date February 2024
Source Abant Izzet Baysal University
Contact Sinem KURTOGLU, Phd Student
Phone 90 374 253 45 20
Email sinem.nehirrr@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research is a randomized controlled, experimental study planned to evaluate the effect of diabetes coaching on diabetes self-management, glycosylated hemoglobin and diabetes distress levels in individuals with type 2 diabetes. The research is planned to start on 01.01.2024. Participants will be divided into experimental and control groups using the block randomization method. Participants in the experimental group will first receive 8 sessions of diabetes coaching every 10 days after the chemistry interview. No intervention will be made to the control group. The preliminary implementation of the research will be carried out with 4 individuals with diabetes who voluntarily accept participation and meet the inclusion criteria. Data will be collected by face-to-face interview method. Data will be analyzed with IBM SPSS V23 program.


Description:

Diabetes is a chronic and metabolic disease that develops when the body cannot secrete enough insulin or the cells cannot use insulin as they should, causing damage to many tissues and organs. It is estimated that there are 537 million adults aged 20-79 in the world with diabetes and this number will reach 783 million in 2045. Diabetes distress, which is one of the most common mental concerns in individuals with diabetes, makes it difficult to achieve glycemic control, paves the way for the development of diabetes complications and reduces the quality of life. Diabetes distress also causes an increase in the risk of mortality and morbidity. One of the best ways to prevent or reduce diabetes distress is to provide self-management skills and support. In recent years, health coaching has attracted attention in many countries for improving patients' self-management and providing the necessary behavioral change. In this study, the effect of coaching intervention applied to individuals with diabetes on diabetes self-management, HbA1c and diabetes distress will be investigated.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 64
Est. completion date December 31, 2027
Est. primary completion date December 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Volunteering to participate in the study, - Having been diagnosed with Type 2 diabetes for at least 1 year, - Being between the ages of 18-65, - No communication problems, - Being literate, - Being able to use a phone (home or mobile phone), - Lack of diagnosis of psychiatric disease, - Not receiving hospital treatment due to acute problems, - Not to be involved in another study involving a similar intervention during the research period Exclusion Criteria: - Being diagnosed with type 1 diabetes, - Type 2 diabetes diagnosis period is less than one year, - Being under 18 years of age, over 65 years of age, - Being pregnant, - Having a diagnosis of psychiatric disease, - Not agreeing to participate in the research

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Diabetes coaching
Diabetes coaching intervention will be provided to the participants in the intervention group by the researcher, who is a specialist nurse who has received 140 hours of Level 2 Professional Coaching Training and 20 hours of diabetes coaching training. Since each individual's needs and values will be different, diabetes coaching interventions will be tailored specifically to the individual by the researcher within the general coaching framework, but by taking into account the individual's views, awareness, needs and current situation regarding self-management regarding diabetes. This flexibility, which supports the individual-specific approach within the coaching paradigm, is among the key elements in the success of coaching interventions (43). The individual will determine the coaching agenda according to his/her own needs.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Abant Izzet Baysal University

Outcome

Type Measure Description Time frame Safety issue
Primary Type 2 Diabetes Self-Management Scale This scale was developed by Koç and Özkan to evaluate self-management in type 2 diabetics and is a 5-point Likert type ("Always=5", "Often=4", "Sometimes=3") , "Rarely=2", "Never=1"). The sub-dimensions of the scale, which consists of a total of 19 questions; "Healthy Lifestyle Behaviors" (11 items), "Use of Health Services" (4 items) and "Blood Sugar Management" (4 items). The highest score that can be obtained from the scale is 95 and the lowest score is 19. As the score obtained from the scale increases, diabetes self-management increases. The Cronbach alpha value of the scale was calculated as 0.856 (37) 3 months
Secondary Diabetes Distress Scale The Diabetes Distress Scale is a 17-item, 6-point Likert type scale developed by Polonsky et al. in 2005 to evaluate diabetes-specific distress. The scale consists of four subscales: emotional burden, doctor-related distress, treatment-related distress, and interpersonal distress. Each question in the scale is scored between 1 point and 6 points, and the scale evaluates the distress experienced by the individual in the last month (40). The validity and reliability study of the scale was conducted by Çakilli et al. in 2015, and the a value was found to be 0.88 for the entire scale and 0.90 for each of the subscales. The average total score of the scale is calculated by dividing the total score of the answers given to the scale by 17. A score of 3 points or higher suggests the presence of distress. Score calculation for the sub-dimensions is obtained by dividing the total score of the answers given to the questions by the number of questions in that section (40,41) 3 months
Secondary HbA1c Monitoring Form This is the form created to monitor the HbA1c values of individuals with diabetes before and after the application and to follow the changes (Annex 3). HbA1c is a routine test evaluated every three months in the follow-up of individuals with diabetes. Individuals will be included in the study if they have HbA1c tests within the last 10 days when they come to the Family Health Care, otherwise they will be included in the study when they have the test done on a date suitable for routine control. 3 months
Secondary Introductory Features Form The form was prepared by the researcher by conducting a literature review and consists of a total of 23 questions (32,34,37-39). In this form, in the first section; Questions about age, gender, education level, marital status, perceived income level, who the individual lives with, smoking and alcohol use, and the presence of chronic diseases. In the second part, there are questions about diabetes; duration of diabetes diagnosis, type of diabetes treatment, status of receiving diabetes education, HbA1c value measured in the last 10 days, presence and types of complications due to diabetes, regular use of diabetes medications, how diabetes care is carried out, status of receiving diabetes education (from whom, training subject , when it was taken, etc.) are included 3 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2